Observational Survey Assessing the Factors of Treatment Intensification in Uncontrolled Hypertensive Patients Under a Combination Therapy, Either Fixed or Not, of a Renin-Angiotensin System Blocker (RASB) and Hydrochlorothiazide (HCTZ), According to Their Level of Cardiovascular Risk.

Trial Profile

Observational Survey Assessing the Factors of Treatment Intensification in Uncontrolled Hypertensive Patients Under a Combination Therapy, Either Fixed or Not, of a Renin-Angiotensin System Blocker (RASB) and Hydrochlorothiazide (HCTZ), According to Their Level of Cardiovascular Risk.

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Jul 2014

At a glance

  • Drugs Telmisartan (Primary) ; Hydrochlorothiazide; Telmisartan/hydrochlorothiazide
  • Indications Hypertension
  • Focus Therapeutic Use
  • Acronyms BI-INTENS
  • Sponsors Bayer
  • Most Recent Events

    • 11 Oct 2010 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
    • 11 Oct 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Jul 2010 Planned end date changed from 1 Jul 2010 to 1 Oct 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top